ASSOCIATION OF HPV16 VIRAL LOAD IN GENE L2 WITH CANCER STAGES AND DEMOGRAPHIC CHARACTERISTICS IN CERVICAL CANCER PATIENTS FROM DHI-QAR PROVINCE, IRAQ

Background. Human papillomavirus (HPV) infection, especially high-risk HPV16, is a risk factor for cervical cancer. HPV16 genotype demographic variations may affect carcinogenicity. HPV16 mutations and HPV16 DNA concentration were examined in cervical cancer development in Dhi-Qar province, Iraq. Aim of the study. The study endeavors to elucidate the demographic profile and the correlation between highrisk human papillomavirus type 16 and the susceptibility to cervical cancer in Dhi-Qar Province, Iraq, alongside comprehending the genetics of the minor capsid protein L2. The findings of the research could potentially aid in the timely detection of cervical cancer and enhance the efficacy of measures aimed at preventing and managing cervical cancer. Material and Methods. 93 cervical cancer patients and 60 healthy controls participated in a 2017-2020 casecontrol research. L2 gene amplification detected HPV. HPV16 DNA concentration and demographic variations were assessed in cervical cancer patients. Results. HPV16 infected 65% of cervical cancer patients, with a substantially greater viral load (1043.25±8.50 IU/ml) than healthy persons (91.25±2.90). Cervical cancer was more common in women aged 43-52 (37%) and 32-42 (30%). HPV16 infections peaked in 2019 (78%) and 2020 (69%), with older women having less infections. HPV16 infections were greatest in cervical cancer stages IV (70%), III (68%), II (60%), and 0 (60%). Conclusion. HPV16 infections are rising among young women in Dhi-Qar province, Iraq, and HPV16 DNA concentration is associated with cervical cancer. The data suggest demographic differences in HPV16 genotype development of cervical cancer.

[1]  Lihui Wei,et al.  The application of BMRT-HPV viral load to secondary screening strategies for cervical cancer , 2020, PloS one.

[2]  V. Treviño,et al.  Multiple HPV Infections and Viral Load Association in Persistent Cervical Lesions in Mexican Women , 2020, Viruses.

[3]  Jane J. Kim,et al.  Projected time to elimination of cervical cancer in the USA: a comparative modelling study. , 2020, The Lancet. Public health.

[4]  Rita Kundu,et al.  Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy , 2020, Frontiers in Microbiology.

[5]  C. Chan,et al.  Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination—Review of Current Perspectives , 2019, Journal of oncology.

[6]  S. Murphy,et al.  Barriers and innovative interventions for early detection of cervical cancer. , 2019, Salud publica de Mexico.

[7]  I. Pity,et al.  Human Papillomavirus Genotyping among Different Cervical Smears in Duhok/Iraq , 2019, Asian Pacific journal of cancer prevention : APJCP.

[8]  Rafael Gutiérrez Campos,et al.  Unusual prevalence of high-risk genotypes of human papillomavirus in a group of women with neoplastic lesions and cervical cancer from Central Mexico , 2019, PloS one.

[9]  E. Altobelli,et al.  HPV‐vaccination and cancer cervical screening in 53 WHO European Countries: An update on prevention programs according to income level , 2019, Cancer medicine.

[10]  Xianping Ding,et al.  Phylogeny and polymorphism in the long control regions E6, E7, and L1 of HPV Type 56 in women from southwest China , 2018, Molecular medicine reports.

[11]  F. Hoppe-Seyler,et al.  The HPV E6/E7 Oncogenes: Key Factors for Viral Carcinogenesis and Therapeutic Targets. , 2017, Trends in microbiology.

[12]  J. Bogers,et al.  Serial measurement of type-specific human papillomavirus load enables classification of cervical intraepithelial neoplasia lesions according to occurring human papillomavirus-induced pathway , 2017, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[13]  H. D. de Melker,et al.  Correlation between viral load, multiplicity of infection, and persistence of HPV16 and HPV18 infection in a Dutch cohort of young women. , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[14]  A. Moscicki,et al.  Population-based prevalence of cervical infection with human papillomavirus genotypes 16 and 18 and other high risk types in Tlaxcala, Mexico , 2016, BMC Infectious Diseases.

[15]  Min Li,et al.  Distribution of high‐risk human papillomavirus genotypes in HPV‐infected women in Beijing, China , 2015, Journal of medical virology.

[16]  R. Roden,et al.  L2, the minor capsid protein of papillomavirus. , 2013, Virology.

[17]  M. Sherman,et al.  Human Papillomavirus Load Measured by Linear Array Correlates with Quantitative PCR in Cervical Cytology Specimens , 2012, Journal of Clinical Microbiology.

[18]  L. Bruni,et al.  Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. , 2010, The Journal of infectious diseases.

[19]  S. Kjaer,et al.  Study Comparing Human Papillomavirus (HPV) Real-Time Multiplex PCR and Hybrid Capture II INNO-LiPA v2 HPV Genotyping PCR Assays , 2009, Journal of Clinical Microbiology.

[20]  J. Berkhof,et al.  High-risk HPV type-specific clearance rates in cervical screening , 2007, British Journal of Cancer.

[21]  U. Gyllensten,et al.  High viral loads of human papillomavirus predict risk of invasive cervical carcinoma , 2005, British Journal of Cancer.

[22]  J. Sautière,et al.  Persistence and load of high‐risk HPV are predictors for development of high‐grade cervical lesions: A longitudinal French cohort study , 2003, International journal of cancer.

[23]  S. Syrjänen,et al.  Integrated Human Papillomavirus Type 16 Is Frequently Found in Cervical Cancer Precursors as Demonstrated by a Novel Quantitative Real-Time PCR Technique , 2002, Journal of Clinical Microbiology.